<DOC>
	<DOCNO>NCT01995136</DOCNO>
	<brief_summary>The purpose study investigate IOP reduction efficacy travoprost 0.004 % ophthalmic solution ( TRAVATAN Z® ) subject normal tension glaucoma .</brief_summary>
	<brief_title>Investigation Intraocular Pressure ( IOP ) Reduction Efficacy Travoprost Ophthalmic Solution Patients With Normal Tension Glaucoma</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Low Tension Glaucoma</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Travoprost</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Diagnosis normal tension glaucoma . Must sign Informed Consent form . IOP within protocolspecified range . Other protocolspecified inclusion criterion may apply . Pregnant lactate woman , woman intend become pregnant study period . Advanced serious glaucoma , specify protocol . Complicated chronic recurrent uveitis , scleritis corneal herpes . History ocular trauma , intraocular surgery laser surgery include eye . Ocularinfection severe ocular complication . Bestcorrected visual acuity ( BCVA ) worse 0.2 decimal . Difficulty conduct applanation tonometry include eye determine doctor . Severe serious hypersensitivity prostaglandin analogues ingredient use study . Use IOP lower ophthalmic solution TRAVATAN Z® oral carbonic anhydrase inhibitor ( Diamox , etc . ) study period . Use adrenocorticosteroids study period . Use IOP lower ophthalmic solution within past 30 day . Regarded doctor suitable study participation . Other protocolspecified exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Glaucoma</keyword>
	<keyword>Ocular hypertension</keyword>
</DOC>